Patents Assigned to Forest Laboratories Holding Limited
  • Patent number: 10702576
    Abstract: The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: July 7, 2020
    Assignees: IRONWOOD PHARMACEUTICALS, INC., FOREST LABORATORIES HOLDINGS LIMITED
    Inventors: Yun Mo, Angelika Fretzen, Brian Cali, Mahendra Dedhiya
  • Patent number: 10675325
    Abstract: The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: June 9, 2020
    Assignees: IRONWOOD PHARMACEUTICALS, INC., FOREST LABORATORIES HOLDINGS LIMITED
    Inventors: Yun Mo, Angelika Fretzen, Brian Cali, Mahendra Dedhiya
  • Patent number: 10660868
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: May 26, 2020
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Suneel K Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G Dedhiya, Shashank Mahashabde
  • Publication number: 20170281722
    Abstract: The invention provides methods for treating a patient with constipation-predominant irritable bowel syndrome by administering a therapeutically effective dose of linaclotide.
    Type: Application
    Filed: June 16, 2017
    Publication date: October 5, 2017
    Applicant: Forest Laboratories Holdings Limited
    Inventors: Jeffrey Johnston, Bernard Joseph Lavins, Harvey Schneier
  • Patent number: 9629861
    Abstract: The present invention relates to compositions comprising ceftaroline or a prodrug thereof (e.g., ceftaroline fosamil) and methods for treating bacterial infections, such as complicated skin and structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP) by administering ceftaroline or a prodrug thereof, (e.g., ceftaroline fosamil).
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: April 25, 2017
    Assignee: FOREST LABORATORIES HOLDING LIMITED
    Inventors: Dirk Thye, George Talbot
  • Patent number: 9580424
    Abstract: The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: February 28, 2017
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Mahendra G. Dedhiya, Sisir Bhattacharya, Véronique Ducandas, Alexandre Giuliani, Valérie Ravaux, Alain Bonnet, Alain Priour, Peter Spargo
  • Patent number: 9283261
    Abstract: The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: March 15, 2016
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Ritesh Sanghvi, Matthew Miller, Andreas Grill, Yun Mo, Mohammad Mafruhul Bari, Matthew Ronsheim, Joseph Stainkamp
  • Patent number: 9221821
    Abstract: Methods for the synthesis of disubstituted aminouracils and xanthine and/or xanthine-related compounds are provided.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: December 29, 2015
    Assignee: Forest Laboratories Holdings, Limited
    Inventors: Nhut Diep, Yuriy B. Kalyan
  • Publication number: 20140349948
    Abstract: The invention provides methods for treating a patient with chronic constipation by administering a therapeutically effective dose of linaclotide.
    Type: Application
    Filed: December 23, 2013
    Publication date: November 27, 2014
    Applicants: Forest Laboratories Holdings Limited, Ironwood Pharmaceuticals, Inc.
    Inventors: Jeffrey Johnston, Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Bernard Joseph Lavins, Mahendra Dedhiya, Harvey Schneier
  • Publication number: 20140287034
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: May 23, 2014
    Publication date: September 25, 2014
    Applicants: Ironwood Pharmaceuticals, Inc., Forest Laboratories Holdings Limited
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • Patent number: 8834924
    Abstract: The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: September 16, 2014
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Yan Yang, Rajiv Janjikhel, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Erhard Seiller, Bernhard Hauptmeier
  • Publication number: 20140162963
    Abstract: The invention provides methods for treating a patient with constipation-predominant irritable bowel syndrome by administering a therapeutically effective dose of linaclotide.
    Type: Application
    Filed: September 9, 2011
    Publication date: June 12, 2014
    Applicants: Forest Laboratories Holdings Limited, Ironwood Pharmaceuticals, Inc.
    Inventors: Jeffrey Johnston, Bernard Joseph Lavins, Harvey Schneier
  • Patent number: 8633241
    Abstract: The present invention provides an improved process for the synthesis of nebivolol or its pharmaceutically acceptable salts, more particularly hydrochloride salt of formula (I). The present invention further provides a new Form T1 of nebivolol and its pharmaceutically acceptable salts. The present invention also provides pharmaceutical compositions and process for the preparation of a solid oral dosage form of nebivolol hydrochloride of formula (I), without the use of wetting agent, and optionally using binder and/or disintegrant.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: January 21, 2014
    Assignee: Forest Laboratories Holdings, Limited
    Inventors: Srinivasarao Veeravenkata Attanti, Hasmukh Mathurbhai Patel, Sunil Sadanand Nadkarni
  • Publication number: 20140005128
    Abstract: The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
    Type: Application
    Filed: August 11, 2011
    Publication date: January 2, 2014
    Applicants: Forest Laboratories Holdings Limited, Ironwood Pharmaceuticals, Inc
    Inventors: Yun Mo, Angelika Fretzen, Brian Cali, Mahendra Dedhiya
  • Patent number: 8604222
    Abstract: The present invention provides an improved process for the synthesis of nebivolol or its pharmaceutically acceptable salts, more particularly hydrochloride salt of formula (I). The present invention further provides a new Form T1 of nebivolol and its pharmaceutically acceptable salts. The present invention also provides pharmaceutical compositions and process for the preparation of a solid oral dosage form of nebivolol hydrochloride of formula (I), without the use of wetting agent, and optionally using binder and/or disintegrant.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: December 10, 2013
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Rakesh Sheth, Srinivasarao Veeravenkata Attanti, Hasmukh Mathurbhai Patel, Vinodkumar Gupta, Sunil Sadanand Nadkarni
  • Publication number: 20130190239
    Abstract: The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions.
    Type: Application
    Filed: March 15, 2013
    Publication date: July 25, 2013
    Applicants: Forest Laboratories Holdings Limited, Ironwood Pharmaceuticals, Inc.
    Inventors: Ironwood Pharmaceuticals, Inc., Forest Laboratories Holdings Limited
  • Publication number: 20130109646
    Abstract: A method for treating glaucoma or ocular hypertension by administering to a patient a pharmacologically effective amount of a compound represented by the following formula (1) or a salt thereof: , wherein X represents CH or N; R1 represents a hydrogen atom, a hydroxy group, a halogen atom, an alkyl group, an alkoxy group, a cycloalkyl group, a cycloalkoxy group, a (cycloalkyl)alkoxy group, or R2 represents a hydrogen atom, an alkyl group, a cycloalkyl group, an alkylcarbonyl group or an alkyloxycarbonyl group; and Ra and Rb each represent a hydrogen atom, a hydroxy group, a halogen atom, an alkyl group, an alkoxy group, a cycloalkyl group or a cycloalkoxy group.
    Type: Application
    Filed: December 20, 2012
    Publication date: May 2, 2013
    Applicants: FOREST LABORATORIES HOLDINGS LIMITED, SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: SANTEN PHARMACEUTICAL CO., LTD., FOREST LABORATORIES HOLDINGS LIMITED
  • Publication number: 20130059797
    Abstract: The invention provides methods for treating a patient with chronic constipation by administering a therapeutically effective dose of linaclotide.
    Type: Application
    Filed: November 3, 2010
    Publication date: March 7, 2013
    Applicants: Forest Laboratories Holdings Limited, Ironwood Pharmaceuticals ,Inc.
    Inventors: Jeffrey Johnston, Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Bernard Joseph Lavins, Mahendra Dedhiya, Harvey Schneier
  • Publication number: 20130012454
    Abstract: The present invention relates to orally disintegrating or dissolving pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well to various methods and processes for the preparation and use of the compositions.
    Type: Application
    Filed: August 11, 2010
    Publication date: January 10, 2013
    Applicants: Ironwood Pharmaceuticals, Inc., Forest Laboratories Holdings Limited
    Inventors: Yun Mo, Mahendra Dedhiya, Anil Chhettry, Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao
  • Publication number: 20120213846
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: August 14, 2009
    Publication date: August 23, 2012
    Applicants: Forest Laboratories Holdings Limited, Ironwood Pharmaceuticals, Inc.
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo